Long Term Antipsychotic Use In Kids Okay With FDA, But Panel Has Concerns
Executive Summary
Not only did three antipsychotic drugs receive FDA advisory committee endorsement June 10 for the acute treatment of schizophrenia and bipolar disorder in pediatric populations, but FDA said that if the sNDAs are approved, it will likely extrapolate pediatric maintenance claims from the adult data
You may also be interested in...
FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel
Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.
Pediatric Labeling Extrapolation From Adults To Be Addressed In FDA Manual
FDA's Office of Pediatric Therapeutics expects to develop by 2012 a manual to guide agency staff on the use of extrapolation when assessing pediatric products and their development programs
Pediatric Labeling Extrapolation From Adults To Be Addressed In FDA Manual
FDA's Office of Pediatric Therapeutics expects to develop by 2012 a manual to guide agency staff on the use of extrapolation when assessing pediatric products and their development programs